Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
BMJ Health & Care Informatics|June 15, 2022
Designing an electronic medical record alert to identify hospitalised patients with HIV: successes and challengesWalid El-Nahal, Thomas Grader-Beck, Kelly Gebo, et al.
Cureus|September 10, 2019
Clinical Characteristics of Hydralazine-induced LupusHoma Timlin, Michael Wu, Monica Crespo-Bosque, et al.
Ophthalmology|September 3, 2014
Ocular and systemic morbidity in a longitudinal cohort of Sjögren's syndromeEsen Karamursel Akpek, Priya Mathews, Sarah Hahn, et al.
Rheumatology (Oxford, England)|March 9, 2024
Characteristics associated with patient-reported treatment success in psoriatic arthritisChristeen Samuel, Amanda Finney, Thomas Grader-Beck, et al.
Arthritis Care & Research|March 20, 2021
Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying TherapiesBerkan Armağan, Susan A Robinson, Adriana Bazoberry, et al.
American Journal of Ophthalmology|June 21, 2015
Ocular complications of primary Sjögren syndrome in menPriya M Mathews, Sarah Hahn, Michelle Hessen, et al.
Obesity Science & Practice|February 13, 2025
Centering Weight Management Clinical Decision Support in Primary Care on Patients With Obesity and Practitioners: A Proof-Of-Concept StudyKimberly A Gudzune, Jessica L Schwartz, Kelly Olsson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Elevation of intracellular cyclic AMP in alloreactive CD4(+) T Cells induces alloantigen-specific tolerance that can prevent GVHD lethality in vivoMatthew J O'Shaughnessy, Zong-Ming Chen, Irene Gramaglia, et al.
Lancet (London, England)|December 3, 2021
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trialSimon J Bowman, Robert Fox, Thomas Dörner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 18, 2024
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging StudyThomas Dörner, Simon J Bowman, Robert Fox, et al.
Pageof 3